SAN FRANCISCO—Patients with intermediate-risk metastatic renal cell carcinoma (mRCC) appear to have divergent ... Sloan-Kettering Cancer Center/Motzer (MSKCC/Motzer) model.

The MSKCC classification system was based on a retrospective analysis of the clinical and biological characteristics of patients treated for mRCC with various therapeutic protocols of chemotherapy ...

Temsirolimus was first evaluated in patients with mRCC in a randomized Phase II study ... participants were retrospectively classified according to MSKCC prognostic criteria, revealing a longer ...

Conclusions: Bevacizumab plus IFN-alpha prolonged both OS and PFS as first line therapy for mRCC, especially for MSKCC intermediate risk group. The toxicity was acceptable and well tolerated. No ...

A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer. This is an ASCO Meeting Abstract from the 2014 Genitourinary Cancers Symposium. This ...

Standard of Care for mRCC May Change Jody A. Charnow | Publish Date April 4, 2019 Data support first-line treatment with combined regimens that include an immunotherapeutic agent ...

Treating mRCC patients with poor-risk features remains ... particularly for patients that are at intermediate risk according to classical MSKCC criteria.